| Exviera (dasabuvir) / AbbVie |
NCT00851890: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection |
|
|
| Completed | 2 | 30 | US | ABT-333, dasabuvir, Placebo for ABT-333, Pegylated interferon, Ribavirin | AbbVie (prior sponsor, Abbott) | Chronic Hepatitis C Virus Infection | 07/09 | 07/09 | | |
NCT00726882: A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies |
|
|
| Completed | 2 | 35 | US | Blood sample collection only, ABT-333, dasabuvir | AbbVie (prior sponsor, Abbott) | HCV Infection | 05/10 | 05/10 | | |
Champion2, NCT01074008: A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 |
|
|
| Completed | 2 | 74 | US | ABT-450, ABT-072, ABT-333, Dasabuvir, Ritonavir, ABT-538, Norvir, Peginterferon alpha-2a, Ribavirin, Placebo | AbbVie (prior sponsor, Abbott) | Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1 | 06/11 | 01/12 | | |
|
|
NCT01306617: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection |
|
|
| Completed | 2 | 50 | US | ABT-450, ABT-333, dasabuvir, ribavirin, ritonavir, Norvir | AbbVie (prior sponsor, Abbott) | Chronic Hepatitis C Infection, Hepatitis C, Hepatitis C Virus | 11/11 | 10/12 | | |
|
|
|
|
NCT01563536: Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects |
|
|
| Completed | 2 | 12 | US | ABT-267, ombitasvir, ABT-450, ABT-333, dasabuvir, Ritonavir, Ribavirin | AbbVie (prior sponsor, Abbott) | Chronic Hepatitis C Infection | 04/12 | 06/13 | | |
|
NCT01464827 / 2010-022455-31: ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients |
|
|
| Completed | 2 | 580 | US, Canada, Europe, RoW | ABT-450, ABT-333, Dasabuvir, ABT-267, Ombitasvir, Ribavirin, Ritonavir, Norvir | AbbVie (prior sponsor, Abbott) | Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1 | 03/13 | 09/13 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT01911845: An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine |
|
|
| Completed | 2 | 38 | NA | ABT-450/r/ABT-267, ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir, ABT-333, dasabuvir, Ribavirin (RBV) | AbbVie | Chronic Hepatitis C Infection, Chronic Hepatitis C | 12/13 | 09/14 | | |
|
NCT01995071: A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV) |
|
|
| Completed | 2 | 89 | NA | ABT-493, glecaprevir, ABT-530, pibrentasvir, ABT-450/r/ABT-267, ABT-333, ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ABT-333 also known as dasabuvir, Viekira PAK, Ribavirin (RBV) | AbbVie | Chronic Hepatitis C, Hepatitis C Virus, Compensated Cirrhosis | 06/15 | 06/15 | | |
NCT02493855 / 2014-001478-32: Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults |
|
|
| Completed | 2 | 46 | NA | Ombitasvir/ABT-450/Ritonavir, ABT-267/ABT-450/ritonavir, Dasabuvir, ABT-333, Ribavirin (RBV) | AbbVie | Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1a | 04/16 | 12/16 | | |
NCT02356562: A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection |
|
|
| Completed | 2 | 29 | NA | ombitasvir/paritaprevir/ritonavir and dasabuvir, ABT-450/r/ABT-267, Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333, Sofosbuvir, Sovaldi, Ribavirin, RBV | AbbVie | Chronic Hepatitis C Infection | 10/16 | 07/17 | | |
| Completed | 2 | 129 | NA | ombitasvir/paritaprevir/ritonavir and dasabuvir, Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333, ombitasvir/paritaprevir/ritonavir, TECHNIVIE, ribavirin | AbbVie | Chronic Hepatitis C Infection | 11/16 | 07/17 | | |
|
|
|
|
C_ASCENT, NCT02194998: Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy |
|
|
| Terminated | 2 | 46 | US | Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), Dasabuvir (DSV), Ribavirin (RBV) | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections, Hepatitis C | 05/18 | 11/18 | | |
| Completed | 2 | 408 | Europe | Viekirax, Exviera (Dasabuvir), Harvoni, Ribavirin (film-coated 200mg), Ribavirin (hard capsule, 200mg), Ribavirin (film-coated, 400mg), Maviret, Film-coated tablet, , Viekirax, Exviera (Dasabuvir), Harvoni, Maviret | Imperial College London, NIHR Efficacy and Mechanism Evaluation Programme | Hepatitis C Infection (HCV) (genotype 1a/1b/4), Hepatitis C infection, Diseases [C] - Virus Diseases [C02] | | | | |
